Global Breast Cancer Screening and Diagnostic Techniques Market - 2025-2033

The global breast cancer screening and diagnostic techniques market reached US$ 6.8 billion in 2024 and is expected to reach US$ 11.7 billion by 2033, growing at a CAGR of 6.3% during the forecast period 2025-2033.

Breast cancer screening and diagnostic techniques refer to a range of medical procedures, tests, and technologies used to detect, diagnose, and evaluate breast cancer, either before symptoms appear or in individuals presenting with symptoms. These methods aim to identify breast cancer in its earliest stages, improving the chances of successful treatment and survival.

Screening involves checking for signs of breast cancer in people who do not have any noticeable symptoms, with the goal of detecting cancers early when treatment is most effective. Once a potential abnormality is identified through screening, diagnostic techniques are used to confirm whether it is cancer and to assess its type and extent.

The breast cancer screening and diagnostic techniques market is experiencing increasing demand, driven by factors such as a rising incidence of breast cancer, advances in technology, and growing awareness of the importance of early detection. For instance, initiatives such as the Pink Ribbon Campaign and Breast Cancer Awareness Month (October) have significantly increased global awareness, encouraging women to undergo regular screening.

Market Dynamics: Drivers & Restraints

Rising prevalence of breast cancer

The rising prevalence of breast cancer is significantly driving the growth of the breast cancer screening and diagnostic techniques market and is expected to drive the market over the forecast period. Breast cancer is now the most commonly diagnosed cancer worldwide, with its prevalence continuously increasing due to factors like population aging, lifestyle changes, and improved diagnostic capabilities. This directly impacts the demand for early detection and diagnostic technologies.

For instance, according to the World Health Organization (WHO), in 2022, 2.3 million women were diagnosed with breast cancer. Breast cancer affects women of all ages after puberty, although the incidence rises later in life. Additionally, according to the Breast Cancer Organization, in 2024, approximately 310,720 women diagnosed with invasive breast cancer, 16% of which will be in women younger than 50 years of age in the United States. The growing number of cases drives the need for comprehensive screening and diagnostic tools for early detection and treatment.

As lifestyle changes and genetic predispositions contribute to the rising incidence of breast cancer, the need for preventive screening and diagnostic techniques grows. Women with a family history of breast cancer or genetic mutations (like BRCA1/2) are at a much higher risk. Genetic testing, which is becoming more widely available, is in high demand for women at elevated risk.

Limited accuracy & standardization in AI-driven diagnostics

The integration of Artificial Intelligence (AI) into breast cancer screening and diagnostics holds significant promise. However, challenges related to limited accuracy and lack of standardization are impeding its widespread adoption. AI models trained on non-diverse datasets may not generalize well across varied populations. For instance, an AI system developed using data from one demographic may underperform when applied to another, leading to inconsistent diagnostic outcomes. This variability can result in both false positives and false negatives, undermining trust in AI-driven diagnostics.

AI algorithms may struggle to identify specific forms of breast cancer, such as interval cancers (ICs), which are aggressive and often elude standard screening methods. Despite efforts to enhance detection, ICs account for approximately 30% of detected breast cancers, and AI's success in improving their detection has been limited.

Segment Analysis

The global breast cancer screening and diagnostic techniques market is segmented based on product type, technology, end-user and region.

Product Type:

The imaging techniques segment is expected to dominate the breast cancer screening and diagnostic techniques market share

Mammography remains the gold standard in breast cancer screening, which significantly drives the demand for imaging technologies in this market. Mammography is highly effective in detecting early-stage breast cancer, particularly in women over 40. The technique allows radiologists to identify suspicious lumps, microcalcifications, or other abnormalities that could indicate cancer.

For instance, in November 2024, GE HealthCare launched its new Pristina Via mammography system which is designed to enhance the breast screening experience for both technologists and patients. Pristina enhancements will help decrease repetitive tasks and improve processes, allowing mammography techs to concentrate on delivering quality and personalized care.

Ultrasound is frequently used as a supplementary imaging technique alongside mammography to further assess abnormalities or to guide biopsies. Ultrasound is particularly beneficial for women with dense breast tissue, where mammograms might miss certain cancers. It is also effective in distinguishing between solid tumors and benign cysts, reducing unnecessary biopsies.

For instance, in December 2024, the novel ultrasound measurement and monitoring technology launched for early breast cancer detection. This Sona's technology enables women to proactively monitor their breast health before they are old enough to access a mammogram. It enables healthcare providers to provide timely personalised screening through simple, safe and low-cost access to breast density information, which is currently limited by a woman's age and use of traditional mammograms.

Geographical Analysis

North America is expected to hold a significant position in the breast cancer screening and diagnostic techniques market share

The rising number of breast cancer cases in North America especially in the United States and Canada is a significant driver for the increased demand for screening and diagnostic techniques in the region. According to the Breast Cancer Organization, 310,720 women diagnosed with invasive breast cancer. This high incidence directly translates to a growing need for screening and diagnostic technologies.

Additionally, according to the Canadian Cancer Society, in 2022, an estimated 28,600 Canadian women diagnosed with breast cancer. Breast cancer is responsible for around 25% of new cancer diagnoses and among Canadian women. One in every eight women is anticipated to acquire breast cancer over her lifetime. This contributes to the high demand for early detection technologies.

Awareness campaigns and high public knowledge about the importance of early breast cancer detection have significantly increased demand for screening and diagnostic tests in North America. For instance, October is recognized as Breast Cancer Awareness Month in North America, during which public campaigns increase awareness about the importance of routine screening and early detection, driving higher participation in screening programs.

Asia-Pacific is growing at the fastest pace in the breast cancer screening and diagnostic techniques market

Many Asia-Pacific countries are investing significantly in improving healthcare infrastructure, which is directly impacting the adoption of advanced breast cancer screening and diagnostic techniques. Countries like China, India, Japan, and South Korea are making substantial investments in healthcare infrastructure. For instance, China and India has implemented national cancer screening programs that increase access to mammography and ultrasound technologies in rural areas.

The rise of private hospitals and healthcare facilities in countries like India and Southeast Asia has significantly increased access to advanced breast cancer diagnostic tools. Major private hospitals in cities like Mumbai and Singapore now offer state-of-the-art diagnostic services, including 3D mammography, MRI, and AI-powered diagnostics. For instance, in December 2024, Deepak Phenolics Limited unveiled a transformative initiative with the launch of a Mobile Mammography Van (MMV) designed to detect breast cancer at its early stages.

The rising awareness about breast cancer and increasing governmental support in the APAC region especially in India and China are pivotal to the growth of the screening and diagnostic market. For instance, in January 2025, Fujifilm India launched brand film Maa's fight through my eyes under the series Stories of More Smiles, highlighting breast cancer awareness initiative

Competitive Landscape

The major global players in the breast cancer screening and diagnostic techniques market include GE HealthCare, Hologic, Inc., Koninklijke Philips N.V., Siemens Healthineers AG, FUJIFILM Holdings Corporation, Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, Danaher Corporation, QIAGEN N.V., Bio-Rad Laboratories, Inc. and among others.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Breast Cancer Screening and Diagnostic Techniques market report delivers a detailed analysis with 62 key tables, more than 55 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.